Posted by Michael Wonder on 11 Mar 2020
Decision to widen funded access to lenalidomide for multiple myeloma
11 March 2020 - PHARMAC is pleased to announce a decision to widen funded access to lenalidomide (Revlimid) to include maintenance treatment for people with newly diagnosed multiple myeloma who have undergone autologous stem cell transplant, through an agreement with Celgene.
In summary the decision will result in the following changes from 1 April 2020:
- lenalidomide (Revlimid) will be funded as maintenance treatment for people with newly diagnosed multiple myeloma who have undergone autologous stem cell transplant
- a new 5 mg capsule strength of lenalidomide will be funded, to make dosage adjustments easier for any of the funded indications.
